Evidence map›Paper›PMID 28950307›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.

A Oseledchyk, M M Leitao, J Konner, R E O'Cearbhaill, D Zamarin, Y Sonoda, G J Gardner, K Long Roche, C A Aghajanian, R N Grisham and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  18. Article
  19. Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

A OseledchykDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York.
M M LeitaoGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York.
J KonnerGynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
R E O'CearbhaillGynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
D ZamarinGynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Y SonodaGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York.
G J GardnerGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York.
K Long RocheGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York.
C A AghajanianGynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
R N GrishamGynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
C L BrownGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York.
A SnyderGynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
D S ChiGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York.
R A SoslowGynecologic Pathology, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
N R Abu-RustumGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York.
O ZivanovicGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundWe sought to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I endometrioid epithelial ovarian cancer (EEOC) or ovarian clear cell cancer (OCCC) using a national database. PATIENTS AND

methodsThe Surveillance, Epidemiology, and End Results database was used to identify patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I EEOC or OCCC from 2000 to 2013. We sought to identify predictors of chemotherapy use and to assess the impact of chemotherapy on OS in these patients. OS was compared using the log-rank test and the Cox proportional hazards model.

resultsIn all, 3552 patients with FIGO stage I EEOC and 1995 patients with stage I OCCC were identified. Of the 1600 patients (45%) with EEOC who underwent adjuvant chemotherapy, the 5-year OS rate was 90%, compared with 89% for those who did not undergo adjuvant chemotherapy (P = 0.807). Of the 1374 (69%) patients with OCCC who underwent adjuvant chemotherapy, the 5-year OS rate was 85%, compared with 83% (P = 0.439) for those who did not undergo adjuvant chemotherapy. Chemotherapy use was associated with younger age, higher substage, and more recent year of diagnosis for both the EEOC and OCCC groups. Only in the subgroup of patients with FIGO substage IC, grade 3 EEOC (n = 282) was chemotherapy associated with an improved 5-year OS-81% compared with 62% (P = 0.003) in untreated patients (HR: 0.583; 95% CI: 0.359-0.949; P = 0.030). In patients with OCCC, there was no significant effect of adjuvant chemotherapy on OS in any substage.

conclusionsAdjuvant chemotherapy was associated with improved OS only in patients with substage IC, grade 3 EEOC. In stage I OCCC, adjuvant chemotherapy was not associated with improved OS.

Indexed as

Adenocarcinoma, Clear CellAdolescentAdultAgedAged, 80 and overCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoplasms, Glandular and EpithelialNeoplasm StagingOrganoplatinum CompoundsOvarian NeoplasmsProportional Hazards ModelsOrganoplatinum Compoundsadjuvant chemotherapyendometrioid ovarian cancerovarian cancerovarian clear cell cancerSEERstage I

Identifiers

PMID28950307
PMCPMC5834056
OpenAlexW2754235234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.